Lupin is currently trading at Rs. 772.00, down by 11.10 points or 1.42% from its previous closing of Rs. 783.10 on the BSE.
The scrip opened at Rs. 771.90 and has touched a high and low of Rs. 779.20 and Rs. 736.10 respectively. So far 444555 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 720.40 on 28-Mar-2019.
Last one week high and low of the scrip stood at Rs. 866.00 and Rs. 736.10 respectively. The current market cap of the company is Rs. 34918.35 crore.
The promoters holding in the company stood at 46.97%, while Institutions and Non-Institutions held 38.07% and 14.96% respectively.
The United States Food and Drug Administration (USFDA) has completed inspection at Lupin’s Aurangabad manufacturing facility. The inspection was carried out from May 6 to May 15, 2019.
The inspection at the Aurangabad facility closed with three observations. The company is confident of addressing them satisfactorily.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
